Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer

PURPOSE: We have previously described a novel pathway controlling drug resistance, epithelial-to-mesenchymal transition (EMT) and stemness in breast cancer cells. Upstream in the pathway, three miRs (miR-106b, miR-93 and miR-25) target EP300, a transcriptional activator of E-cadherin. Upregulation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Asaduzzaman, Muhammad, Constantinou, Stephanie, Min, Haoxiang, Gallon, John, Lin, Meng-Lay, Singh, Poonam, Raguz, Selina, Ali, Simak, Shousha, Sami, Coombes, R. Charles, Lam, Eric W.-F., Hu, Yunhui, Yagüe, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427146/
https://www.ncbi.nlm.nih.gov/pubmed/28341962
http://dx.doi.org/10.1007/s10549-017-4202-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427146/
https://www.ncbi.nlm.nih.gov/pubmed/28341962
http://dx.doi.org/10.1007/s10549-017-4202-z

Ejemplares similares